Back grey_arrow_rt.gif
Rosiglitazone- Diabetes Drug -Could Help Lessen Metabolic Side Effects of Antiretroviral Drug Regimens
  A drug usually prescribed to diabetics could help HIV-positive patients on highly active antiretroviral therapy better manage naturally occurring insulin and reduce some of the metabolic side effects of the treatment, according to a study published in the May 18 issue of the Annals of Internal Medicine, Reuters reports. Some HIV-positive patients taking HAART experience a loss of body fat, called lipoatrophy, or an odd redistribution of fat on the shoulders or around the internal organs, which can be dangerous. In addition, some patients lose the fat in their faces, which can give them a gaunt look, according to Reuters. Researchers from Massachusetts General Hospital and Harvard Medical School in Boston studied 27 HIV-positive patients who were on HAART and had insulin sensitivity -- a measure of diabetes risk -- and lipoatrophy. For three months, the patients received either a placebo or GlaxoSmithKline's diabetes drug Avandia, known generically as rosiglitazone. The patients taking Avandia had a 20% improvement in insulin insensitivity, according to the study. "The metabolic complications of this condition are becoming more significant as patients spend more time on HAART," lead author Dr. Colleen Hadigan said, adding, "For example, we now know that 14% of men on this therapy may develop type 2 diabetes, which is four times the usual risk; and concerns are also increasing about the related risk of heart disease." Hadigan said, "We were able to demonstrate that this class of agents can slow down or reverse fat loss in patients with fat atrophy." However, Hadigan concluded that certain patient safety issues need to be resolved before the results canbe "widely applied" (Reuters, 5/17).


Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
  icon paper stack View Older Articles   Back to Top